



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : 09/926,323
Applicant : SCHMITT et al
Filed : March 5, 2002
TC/A.U. : 1643
Examiner : Sheela J. Huff

Docket No. : 2923-508
Customer No. : 6449
Confirmation No. : 5188

RESPONSE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

June 29, 2006

Dear Sir:

In the Office Action dated March 3, 2006, claims 30-35, in the above-identified U.S. patent application were rejected. Reconsideration of the rejections is respectfully requested in view of the following remarks. Claims 30-35 remain in this application and claims 36-39 have been withdrawn.

In the only remaining rejection, claims 30-35 were rejected under 35 USC §112, first paragraph, as lacking enablement regarding the prognostic relevance of antibodies directed specifically against the epitope 52-60 of uPAR in the determination of the prognosis of the course of cancer disease in cancers other than breast cancer. Applicants respectfully point out that this is incorrect, the data presented in the present application represent only one possible example of the evidence that the detection of uPAR by an antibody directed against the epitope 52-60 of uPAR provides a prognostic means for the course of cancer.